'Malignant melanoma microecosystem': Immunohistopathological insights into the stromal cell phenotype (Review)

Experimental and Therapeutic Medicine

Volumn 2, Issue 3, 2011, Pages 379-384

  Quatresooz, Pascale ^a   Reginster, Marie Annick ^a   Piérard, Gérald E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cancer; Collagen; Dermal extracellular matrix; Fibroblast; Malignant melanoma; Metastasis; Versican

Indexed keywords

BLOOD CLOTTING FACTOR 13A; COLLAGEN; COLLAGEN ALPHA1; COLLAGEN ALPHA5; ELAFIN; LYSOZYME; UNCLASSIFIED DRUG; VERSICAN;

CANCER STEM CELL; CELL MIGRATION; DISTANT METASTASIS; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; LYMPH NODE METASTASIS; MELANOCYTE; MELANOMA; MICROMETASTASIS; PHENOTYPE; REVIEW; RISK FACTOR; SENTINEL LYMPH NODE; TUMOR VASCULARIZATION;

EID: 79953284041     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.221     Document Type: Review

References (69)

1. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev cancer 5: 275-284, 2005.
2. Quatresooz P and Piérard GE: Malignant melanoma: from cell kinetics to micrometastases. Am J Clin Dermatol: Dec. 13, 2010 (E-pub ahead of print).
3. Smolle J, Hofmann-Wellenhof R and Fink-puches R: Melanoma and stroma: an interaction of biological and prognostic importance. Semin cutan Med Surg 15: 326-335, 1996.
4. Bennett DC: Ultraviolet wavebands and melanoma initiation. Pigment cell Melanoma Res 21: 520-524, 2008.
5. Brenner M, Degitz K, Besch R and Berking C Differential expression of melanoma-associated growth factors in keratino-cytes and fibroblasts by ultraviolet A and ultraviolet B radiation. Br J Dermatol 153: 733-739, 2005.
6. Philips N, Keller T and Holmes C: Reciprocal effects of ascorbate on cancer cell growth and the expression of matrix metalloproteinases and transforming growth factor-beta. Cancer Lett 256: 49-55, 2007.
7. Philips N, Conte J, Chen YJ, Natrajan P, Taw M, Keller T, Givant J, Tuason M, Dulaj L, Leonardi D and Gonzalez S: Beneficial regulation of matrix-metalloproteinases and their inhibitors, fibrillar collagens and transforming growth factor-β by Polypodium leucotomos, directly or in dermal fibroblasts, ultraviolet-radiated fibroblasts, and melanoma cells. Arch Dermatol Res 301: 487-495, 2009.
8. Dvorak HF: Tumors: wounds that do not heal. N Engl J Med 315: 1650-1659, 1986.
9. De Wever O and Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 200: 429-447, 2003.
10. Quatresooz P, Piérard-Franchimont C, Paquet P and Piérard GE: Angiogenic fast-growing melanomas and their micrometastases. Eur J Dermatol 20: 302-307, 2010.
11. Piérard GE and Piérard-Franchimont C: Stochastic relationship between the growth fraction and vascularity of thin malignant melanomas. Eur J Cancer 33: 1888-1892, 1997.
12. Piérard-Franchimont C, Henry F, Heymans O and Piérard GE: Vascular retardation in dormant growth-stunted malignant melanomas. Int J Mol Med 4: 403-406, 1999.
13. Wernert N: The multiple roles of tumour stroma. Virchows Arch 430: 433-443, 1997.
14. Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature 411: 375-379, 2001.
15. Dingemans KP, Zeeman-Boeschoten IM, Keep RF and Das PK: Transplantation of colon carcinoma into granulation tissue induces an invasive morphotype. Int J cancer 54: 1010-1016, 1993.
16. Lugassy C and Barnhill RL: Angiotropic malignant melanoma and extravascular migratory metastasis: description of 26 cases with emphasis on a new mechanism of tumor spread. Pathology 36: 485-490, 2004.
17. Claessens N, Piérard GE, Piérard-Franchimont C, Arrese JE and Quatresooz P: Immunohistochemical detection of incipient melanoma micrometastases. Relationship with sentinel lymph node involvement. Melanoma Res 15: 107-110, 2005.
18. Lugassy C and Barnhill RL: Angiotropic melanoma and extravascular migratory metastasis. A review. Adv Anat pathol 14: 195-201, 2007.
19. Quatresooz P, Piérard GE, Piérard-Franchimont C, Humbert P and Piérard S: Introduction to the spectral analysis of microvasculature in primary cutaneous melanoma. Pathol Biol: Feb, 2010 (E-pub ahead of print).
20. Quatresooz P, Arrese JE, Piérard-Franchimont C and Piérard GE: Immunohistochemical aid at risk stratification of melanocytic neoplasms. Int J Oncol 24: 211-216, 2004.
21. Quatresooz P, Piérard-Franchimont C and Piérard GE: Highlighting the immunohistochemical profile of melanocytomas. Oncol Rep 19: 1367-1372, 2008.
22. Quatresooz P, Piérard GE, Piérard-Franchimont C and the Mosan Study Group of Pigmented Tumors: Molecular pathways supporting the proliferation staging of malignant melanoma. Int J Mol Med 24: 295-301, 2009.
23. Quatresooz P, Piérard-Franchimont C, Piérard GE and the Mosan Study Group of Pigmented Tumors: Molecular histology on the diagnostic cutting edge between malignant melanomas and cutaneous melanocytomas. Oncol Rep 22: 1263-1267, 2009.
24. Piérard-Franchimont C, Arrese JE, Nikkels AF, Al Saleh W, Delvenne P and Piérard GE: Factor XIIIa-positive dermal dendrocytes and proliferative activity of cutaneous cancers. Virchows Arch 429: 43-48, 1996.
25. Schatton T and Franck MH: Cancer stem cells and human malignant melanoma. Pigment cell Melanoma Res 21: 39-55, 2007.
26. Rappa G, Fodstad O and Lorico A: The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem cells 26: 3008-3017, 2008.
27. Schatton T, Murphy GF, Frank NY, et al: Identification of cells initiating human melanomas. Nature 451: 345-349, 2008.
28. Cramer SF: Stem cells for epidermal melanocytes. A challenge for students of dermatopathology. Am J Dermatopathol 31: 331-341, 2009.
29. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, van Belle PA, Xu X, Elder DE and Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337, 2005.
30. Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL, Vervaert CE and Seigler HF Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 126: 142-153, 2006.
31. Buac K and Pavan WJ: Stem cells of the melanocyte lineage. Cancer Biomark 3: 203-209, 2007.
32. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ and Tahan SR: Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20: 102-107, 2007.
33. Arrese Estrada J and Piérard GE: Factor XIIIa-positive dendrocytes and the dermal microvascular unit. Dermatologica 180: 51-53, 1990.
34. Quatresooz P, Paquet P, Hermanns-Lê T and Pierard GE: Molecular mapping of Factor XIIIa-enriched dendrocytes in the skin. Int J Mol Med 22: 403-409, 2008.
35. Quatresooz P and Piérard GE: Immunohistochemical clues at aging of the skin microvascular unit. J Cutan Pathol 36: 39-43, 2009.
36. Fullen DR and Headington JT: Factor XIIIa-positive dermal dendritic cells and HLA-DR expression in radial versus vertical growth-phase melanomas. J Cutan Pathol 25: 553-558, 1998.
37. Denton KJ, Cotton DW, Wright A and Hird P: Factor XIIIa in nodular malignant melanoma and Spitz naevi. Br J Dermatol 12: 783-786, 1990.
38. Polak ME, Johnson P, Di Palma S, Higgins B, Hurren J, Borthwick NJ, Jager MJ, Mccormick D and Cree IA: Presence and maturity of dendritic cells in melanoma lymph node metastases. J Pathol 207: 83-90, 2005.
39. Lugassy C, Eyden BP, Christensen L and Escande JP: Angiotumoral complex in human malignant melanoma characterized by free laminin: ultrastructural and immunohistochemical observations. J Submicrosc Cytol Pathol 29: 19-28, 1997.
40. Schaumburg-Lever G, Lever I, Fehrenbacher B, Möller H, Bischof B, Kaiserling E, Garbe C and Rassner G: Melanocytes in naevi and melanomas synthesize basement membrane and basement membrane-like material. An immunohistochemical and electron microscopic study including immunoelectron microscopy. J Cutan Pathol 27: 67-75, 2000.
41. Van Duinen CM, Fleuren GJ and Bruijn JA: The extracellular matrix in pigmented skin lesions: an immunohistochemical study. Histopathology 24: 33-40, 1994.
42. Lugassy C, Kickersin GR, Christensen L, Karaoli T, Le Charpeniter M, Escande JP and Barnhill RL: Ultrastructural and immunohistochemical studies of the periendothelial matrix in malignant melanoma: evidence for an amorphous matrix containing laminin. J Cutan Pathol 26: 78-83, 1999.
43. Lugassy C, Shahsafaei A, Bonitz P, Busam KJ and Barnhill RL: Tumor microvessels in melanoma express the beta-2 chain of laminin. Implications for melanoma metastasis. J Cutan Pathol 26: 222-226, 1999.
44. Quatresooz P and Piérard GE: Immunohistochemical investigation of a 1 (IV) and a 5 (IV) collagen chains in a broad spectrum of melanocytic tumours. Melanoma Res 15: 161-168, 2005.
45. Wight TN: Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 14: 617-623, 2002.
46. Serra M, Miquel L, Domenzain C, Docampo MJ, Fabra A, Wight TN and Bassols A: V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential. Int J cancer 114: 879-886, 2005.
47. Touab M, Villena J, Barranco C, Arumi-Uria M and Bassols A: Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 160: 549-557, 2002.
48. Docampo MJ, Rabanal RM, Miquel-Serra L, Hernandez D, Domenzain C and Bassols A: Altered expression of versican and hyaluronan in melanocytic tumors of dogs. Am J Vet Res 68: 1376-1385, 2007.
49. Gambichler T, Kreuter A, Grothe S, Altmeyer P, Brockmeyer HN and Rotterdam S: Versican overexpression in cutaneous malgnant melanoma. Eur J Med Res 13: 500-504, 2008.
50. Seité S, Moyal D, Richard S, de Rigal J, Lévêque JL, Hourseau C and Fourtanier A: Effects of repeated suberythemal doses of UVA in human skin. Eur J Dermatol 7: 204-209, 1997.
51. Seité S, Zucchi H, Septier D, Igondjo-Tchen S, Senni K and Godeau G: Elastin changes during chronological and photoageing: the important role of lysozyme. J Eur Acad Dermatol Venereol 20: 980-987, 2006.
52. Piérard-Franchimont C, Uhoda I, Saint Léger D and Piérard GE: Androgenic alopecia and stress-induced premature senescence by cumulative ultraviolet light exposure. Exog Dermatol 1: 203-206, 2002.
53. Muto J, Kuroda K, Wachi H, Hirose S and Tajima S: Accumulation of elafin in actinic elastosis of sun-damaged skin: elafin binds to elastin and prevents elastolytic degradation. J Invest Dermatol 127: 1358-1366, 2007.
54. Williams SE, Brown TI, Roghanian A and Sallenave JM: SLPI and elafin: one glove, many fingers. Clin Sci 110: 21-35, 2006.
55. Nozowa F, Hirota M, Okabe A, Shibata M, Iwamura T, Haga Y and Ogawa M: Elastase activity enhances the adhesion of neutrophil and cancer cells to vascular endothelial cells. J Surg Res 94: 153-158, 2000.
56. Yu KS, Lee Y, Kim CM, Park EC, Choi J, Lim DS, Chung YH and Koh SS: The protease inhibitor, elafin, induces p53-dependent apoptosis in human melanoma cells. Int J cancer 127: 1308-1320, 2010.
57. Kamsteeg M, Jansen PA, van Vlijmen-Willems IM, van Erp PE, Rodij-olthuis D, van der Valk PG, Feuth T, Zeeuwen PL and Schalkwijk J: Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. Br J Dermatol 162: 568-578, 2010.
58. Paczesny S, Braun TM, Levine JE, et al: Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2: 13ra2, 2010.
59. Marcoval J, Moreno A, Graells J, Vidal A, Escriba JM, Garcia-Ramirez JM and Fabra A: Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 24: 212-218, 1997.
60. Alonso S, Ortiz P, Pollan M, Pérez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA and Rodriguez-Peralto JL: Progression in cutaneous malignant melanoma is associated with distinct expression profiles. A tissue microarray-based study Am J Pathol 164: 193-203, 2004.
61. Fecher LA, Cummings SD, Keefe MJ and Alani RM: Toward a molecular classification of melanoma. J Clin Oncol 25: 1606-1620, 2007.
62. Plaza JA, Suster D and Perez-Montiel D: Expression of immuno-histochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique. Appl Immunohistochem Mol Morphol 15: 421-425, 2007.
63. Ohsie SJ, Sarantopoulos GP, Cochran AJ and Binder SW: Immunohistochemical characteristics of melanoma. J Cutan Pathol 35: 433-444, 2008.
64. Hamza S: Prognostic parameters of malignant melanoma. Diagn Histopathol 16: 330-336, 2010.
65. Schopfer G, Wellbrock C and Marais R: Melanoma biology and new targeted therapy. Nature 445: 851-857, 2007.
66. Piérard GE, Quatresooz P, Rorive A, Piérard-Franchimont C and Groupe Mosan d'Etude des Tumeurs pigmentaires: Malignant melanoma: conceptual and therapeutic innovations based on translational research. Rev Med Liège 63: 579-584, 2008.
67. Basu B, Biswas S, Wrigley J, Sirohi B and Corrie P: Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Exp Rev Anticancer The 9: 1583-1598, 2009.
68. Sullivan RJ and Atkins MB: Molecular-targeted therapy in malignant melanoma. Exp Rev Anticancer Ther 9: 567-581, 2009.
69. Kerbel RS, Kobayashi H, Graham CH and Lu C: Analysis and significance of the malignant 'eclipse' during the progression of primary cutaneous human melanomas. J invest Dermatol Symp Proc 1: 183-187, 1996.